GlassScriptPhysician profile
Arman Faravardeh
NPI 1467410019
$40,344.70
in general payments reported to CMS, 2019-2025
27 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,634 · 2020: $1,191 · 2021: $5,174 · 2022: $24K · 2023: $843 · 2024: $389 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078 · Consulting Fee: $500 · Education: $19.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.44 |
| Consulting Fee | $500.00 |
| Education | $19.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veloxis Pharmaceuticals, INC. | $37,778.82 | 2019-2025 | Envarsus |
| Astrazeneca Pharmaceuticals LP | $428.18 | 2019-2025 | Farxiga |
| Csl Behring | $343.56 | 2022 | |
| Sanofi-Aventis U.S. LLC | $269.20 | 2022-2025 | |
| Nxstage Medical, INC. | $234.39 | 2022-2024 | Nxstage System One |
| Vifor Pharma, INC. | $197.14 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $147.20 | 2022-2025 | Livtencity |
| Mallinckrodt Hospital Products INC. | $140.41 | 2023 | Terlivaz |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $139.42 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $115.95 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $74.75 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $73.24 | 2022 | |
| Amgen INC. | $67.80 | 2019 | |
| Eurofins Viracor, LLC | $60.12 | 2020-2024 | |
| Amag Pharmaceuticals, INC. | $48.70 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $39.26 | 2019 | |
| Daiichi Sankyo INC. | $35.04 | 2019 | |
| Opko Pharmaceuticals, LLC | $25.68 | 2019 | |
| Baxter Healthcare | $23.30 | 2024 | Renal - Acute |
| Travere Therapeutics, INC. | $19.23 | 2023-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $18.44 | 2024 | Lupkynis |
| Merck Sharp & Dohme LLC | $17.81 | 2025 | Prevymis |
| Akebia Therapeutics INC | $16.78 | 2020 | |
| Calliditas Therapeutics US INC. | $15.96 | 2025 | Tarpeyo |
| E.R. Squibb & Sons, L.L.C. | $14.32 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arman Faravardeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.